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Purpose 
A breakthrough seizure is an epileptic seizure that occurs following a period of seizure freedom on 
antiepileptic drugs.  Despite the severity and consequences of breakthrough seizures very few 
publications exist that examine factors associated with a breakthrough seizure and outcomes 
following such a seizure.  We therefore developed prognostic models for risk of a breakthrough 
seizure, risk of seizure recurrence after a breakthrough seizure, and likelihood of achieving 12-month 
remission following a breakthrough seizure.  
Methods 
We analysed data from the SANAD study. This long-term randomised trial compared treatments for 
patients with newly diagnosed epilepsy. Multivariable regression modelling was used to investigate 
how clinical factors affect the probability of each outcome. 
Results 
34% of recruited patients had a breakthrough seizure.  Of these, 44% achieved a subsequent period 
of 12-month remission.  Significant factors for risk of a breakthrough seizure following 12-month 
remission were neurological insult, number of tonic-clonic seizures by achievement of 12-month 
remission, and time taken to achieve 12-month remission. Significant factors for risk of seizure 
recurrence following a breakthrough seizure were total number of drugs attempted to achieve 12-
month remission, time to achieve 12-month remission prior to breakthrough seizure, and 
breakthrough seizure treatment decision. Significant factors for likelihood of achieving 12-month 
remission after a breakthrough seizure were gender, age at breakthrough seizure, time to achieve 12-
month remission prior to breakthrough, and breakthrough seizure treatment decision. 
Conclusions 
The described models can be used to identify patients most likely to have a breakthrough seizure, 
most likely to have a seizure recurrence following a breakthrough seizure, and most likely to achieve 
12-month remission following a breakthrough seizure. This will help to stratify patients for likely 
outcome following a breakthrough seizure, as for some the breakthrough heralds the development of 
treatment refractoriness, whilst for the majority seizure control will be regained.    
 
